Table 1.
Patient Demographics and Clinical Characteristics
| Glutathione (N=94) |
Placebo (N=91) |
Total (N=185) |
p-value | |
|---|---|---|---|---|
| Age | 0.411 | |||
| Median | 63.0 | 63.0 | 63.0 | |
| Age >50 | 81 (86%) | 79 (87%) | 160 (87%) | 0.902 |
| Race | 0.792 | |||
| White | 88 (94%) | 84 (92%) | 172 (93%) | |
| Black or African-American | 5 (5%) | 5 (6%) | 10 (5%) | |
| Native Hawaiian or Other Pacific Islander | 0 (0%) | 1 (1%) | 1 (1%) | |
| Asian | 1 (1%) | 1 (1%) | 2 (1%) | |
| Gender | 0.412 | |||
| Female | 74 (79%) | 76 (84%) | 150 (81%) | |
| Baseline Neuropathy | 0.942 | |||
| None | 83 (88%) | 80 (88%) | 163 (88%) | |
| Grade 1 | 11 (12%) | 11 (12%) | 22 (12%) | |
| De-bulked Status3 | 0.692 | |||
| No gross residual disease | 22 (49%) | 20 (49%) | 42 (49%) | |
| Optimal4 | 15 (33%) | 11 (27%) | 26 (30%) | |
| Sub-optimally de-bulked | 8 (18%) | 10 (24%) | 18 (21%) | |
| Cancer Type | 0.892 | |||
| Ovarian/fallopian tube/primary peritoneal | 45 (48%) | 41 (45%) | 86 (47%) | |
| Lung | 27 (29%) | 26 (29%) | 53 (29%) | |
| Other | 22 (23%) | 24 (26%) | 46 (25%) | |
| Group | 0.302 | |||
| Weekly | 12 (13%) | 9 (10%) | 21 (11%) | |
| Every 3 weeks | 82 (87%) | 80 (88%) | 162 (88%) | |
| Every 4 weeks | 0 (0%) | 2 (2%) | 2 (1%) | |
| ECOG Performance Score | 0.802 | |||
| 0 | 42 (45%) | 39 (43%) | 81 (44%) | |
| 1 | 47 (50%) | 45 (50%) | 92 (50%) | |
| 2 | 5 (5%) | 7 (8%) | 12 (7%) | |
| Diabetes | 0.142 | |||
| Yes | 8 (9%) | 14 (16%) | 22 (12.0%) | |
| No | 86 (92%) | 76 (84%) | 162 (88%) |
1
Kruskal Wallis test,
2
Chi-Square test,
3
Applicable only to ovarian/fallopian tube/primary peritoneal,
4
No residual tumor mass greater than 1 cm.